<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Profiling of Syngeneic Models by Anti-PD-1, PD-L1 and CTLA-4 Immunotherapeutics and RNAseq Analysis Provides Predictive Biomarkers for Cancer Immunotherapy

 Syngeneic tumor models have long been used in cancer research. The recent clinical success of anti-CTLA-4 and anti-PD1 antibodies contributed to increasing the interest around the use of syngeneic models to evaluate cancer immunotherapy.